



THE PRESCRIBER e-LETTER

Overview of More Restrictive Coverage Changes Effective April 1, 2026

MassHealth evaluates the prior authorization (PA) status for drugs on an ongoing basis and updates the MassHealth Drug List accordingly. The list below outlines changes to the MassHealth Drug List for the rollout effective April 1, 2026, that have been identified as more restrictive in nature.

Change in Prior Authorization Status

Effective April 1, 2026, the following anticonvulsant will require PA.

- pyridostigmine bromide solution – **PA**; A90

Change in MassHealth Brand Name Preferred Over Generic Drug List Status

- Effective April 1, 2026, the following agents will be added to the MassHealth Brand Name Preferred Over Generic Drug List.
 - Cipro HC (ciprofloxacin/hydrocortisone); BP
 - Mavenclad (cladribine tablet) – **PA**; BP
 - Rowasa (mesalamine enema); BP, A90
- Effective April 1, 2026, the following agents will be removed from the MassHealth Brand Name Preferred Over Generic Drug List.
 - Cardura (doxazosin immediate-release); #, M90
 - Daytrana (methylphenidate transdermal) – **PA < 3 years or ≥ 21 years and PA > 1 unit/day; #**
 - Entresto (sacubitril/valsartan tablet) – **PA**
 - Sancuso (granisetrone transdermal system) – **PA**

Deletions

The following drugs have been removed from the MassHealth Drug List because they have been discontinued by the manufacturer.

- Abilify Mycite (aripiprazole tablet with sensor) – **PA**
- Atripla (efavirenz/emtricitabine/tenofovir); #, A90
- Delzicol DR (mesalamine 400 mg delayed-release capsule) – **PA**
- Fentora (fentanyl buccal tablet) – **PA**
- Finacea (azelaic acidgel) – **PA**; A90
- Idacio (adalimumab-aacf) – **PA**
- Ortikos (budesonide extended-release capsule) – **PA**
- Portrazza (necitumumab) – **PA**; MB
- Tarceva (erlotinib) – **PA**; A90

- Zyprexa Zydis (olanzapine 15 mg orally disintegrating tablet) – **PA<10 years and PA > 2 units/day**
- Zyprexa Zydis (olanzapine 5 mg, 10 mg, 20 mg orally disintegrating tablet – **PA < 10 years and PA > 1 unit/day**

The [MassHealth Drug List's Upcoming and Recent Updates](#) page summarizes changes that will become effective on April 1, 2026. Please refer to the updated summary for more information (including other important upcoming changes). Additional information about coverage status and Prior Authorization requirements can be found on the [MassHealth Drug List website](#).

The Prescriber e-Letter is an update designed to enhance the transparency and efficiency of the MassHealth drug prior-authorization (PA) process and the MassHealth Drug List. Each issue highlights key clinical information and updates to the MassHealth Drug List. The Prescriber E-Letter was prepared by the MassHealth Drug Utilization Review Program and the MassHealth Pharmacy Program.